The drug maker indicates that, conservatively, it plans to see 60% to 70% erosion for rituximab (Rituxan, MabThera), trastuzumab (Herceptin), and bevacizumab (Avastin) by 2023, leaving a gap of approximately $9.6 billion for the company to fill.
In an investor presentation given this week, drug maker Roche, the innovator behind multiple blockbuster drugs now facing competition from biosimilars, gave a look inside its strategy for the future.
The drug maker indicates that, conservatively, it plans to see 60% to 70% erosion for rituximab (Rituxan, MabThera), trastuzumab (Herceptin), and bevacizumab (Avastin) by 2023, leaving a gap of approximately $9.6 billion for the company to fill.
To help offset biosimilar competition for rituximab, Roche says it will rely on sales of its obinutuzumab (for which it is also investigating a new indication in lupus nephritis), venetoclax, the investigational antibody mosunetuzumab, and the investigational MDM2 antagonist idasanutlin.
With its brand-name trastuzumab now facing competition in both the United States and the European union, Roche will rely on sales of pertuzumab, a proposed fixed-dose, subcutaneous trastuzumab and pertuzumab combination; and trastuzumab emtansine, an antibody-drug conjugate. Trastuzumab emtansine and pertuzumab in particular, said Roche will offset biosimilar erosion for trastuzumab as uptake in the adjuvant setting has fueled pertuzumab’s sales growth and as patients with residual disease are increasingly treated with trastuzumab emtansine.
As bevacizumab also faces biosimilar competition, Roche looks to atezolizumab, alectinib, entrectinib, and the investigational ipatasertib.
Ranibizumab (Lucentis) is also the target of oncoming biosimilar competition, and already competes for market share in treating eye disorders with off-label bevacizumab and aflibercept; Roche says that it is looking to faricimab, a proposed bispecific monoclonal antibody, to maintain its share of the macular degeneration market. According to Roche, this therapy, if approved, could reduce the treatment burden associated with current therapies, as it could be dosed at intervals of every 6 months or longer with a port delivery system.
The drug maker said that, while it boasted 10 blockbuster drugs in 2018—including rituximab, trastuzumab, and bevacizumab—it could see as many as 14 blockbusters in 2020, given continued performance of the multiple sclerosis drug ocrelizumab and strong sales of the hemophilia A therapy emicizumab, among others.
In its late-stage pipeline are other drugs with large sales potential, including satralizumab, a proposed monoclonal antibody that targets the interleukin-6 receptor and that offers a novel treatment approach for neuromyelitis optica spectrum disorder, and which could compete with Alexion’s eculizumab in that indication.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.